{
  "url": "https://openlegislation.uk/draft-misuse-of-drugs-act-1971-amendment-order-2026/article-2",
  "json_url": "https://openlegislation.uk/draft-misuse-of-drugs-act-1971-amendment-order-2026/article-2.json",
  "legislation": "ukdsi/2026/9780348288254",
  "legislation_title": "The Misuse of Drugs Act 1971 (Amendment) Order 2026",
  "legislation_url": "https://openlegislation.uk/draft-misuse-of-drugs-act-1971-amendment-order-2026",
  "path": "article/2",
  "kind": "article",
  "number": "2",
  "heading": "Amendments to the Misuse of Drugs Act 1971",
  "text": "(1) Schedule 2 to the Misuse of Drugs Act 1971 (controlled drugs) is amended as follows.\n(2) In Part 1 (which specifies the drugs which are subject to control as Class A drugs)—\n(a) in paragraph 1(a)—\n(i) after “Carfentanil.” insert—\n“Chorphine.”;\n(ii) after “Cocaine.” insert—\n“Cychlorphine (N-propionitrile chlorphine).”;\n(iii) after “Etodesnitazene (etazene).” insert—\n“Etodezitramide.”;\n(iv) after “Rolicyclidine.” insert—\n“Spirobrorphine.\nSpirochlorphine (R-6890).”;\n(v) after “N-Desethyl protonitazene.” insert—\n“5,6-Dichlorobrorphine (SR-14968).\n5,6-Dichloro desmethylchlorphine (SR-17018).”;\n(b) in paragraph 1(ea)—\n(i) in paragraph (iii) after “acetyl,” insert “amino,”;\n(ii) in paragraph (iv) after “methyl group” insert “or by a carbamoyl group”;\n(iii) in paragraph (v) after “benzylic carbon” insert “or of a carbon atom of an ethyl link between the benzimidazole system and the phenyl ring”;\n(iv) after paragraph (vii) insert—\n“(viii) by replacement of the methyl group of the benzyl system by an ethyl group to form a phenethyl system.”;\n(c) after paragraph 1(f) insert—\n“(g) any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from AP-237 (bucinnazine) by modification in any of the following ways—\n(i) by substitution to any extent by methyl in the piperazine or phenyl rings;\n(ii) by replacement of the butyryl group by another acyl group containing three, four or five carbon atoms;\n(iii) by substitution in the phenyl ring by a nitro group;\n(iv) by addition of an ethylenic bridge across the piperazine ring.\n(h) any material (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from 1-(1-benzylpiperidin-4-yl)-1,3-dihydro-benzimidazol-2-one by modification in any of the following ways—\n(i) by substitution to any extent on the phenyl ring of the benzimidazolone core by alkyl, alkoxy, halogen, haloalkyl, methylenedioxy, ethylenedioxy, ethyleneoxy or vinylenoxy;\n(ii) by substitution at the 3- position nitrogen of the benzimidazolone core by alkyl, cyanoalkyl or acyl;\n(iii) by substitution to any extent on the phenyl ring of the benzyl group by alkyl, alkoxy, halogen, haloalkyl, methylenedioxy, ethylenedioxy, ethyleneoxy or vinylenoxy;\n(iv) by substitution on the methylene group of the benzyl group by alkyl containing up to three carbon atoms;\n(v) by replacement of the benzyl group by a 3,3-diphenylpropyl, a 3-cyano-3,3-diphenylpropyl or a 4-alkyl-4-oxo-3,3-diphenylbutyl group.\n(i) any material (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from 8-benzyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one by modification in any of the following ways—\n(i) by substitution at the nitrogen at the 3- position of the triazaspiro core by alkyl;\n(ii) by substitution to any extent on the phenyl ring of the benzyl group by alkyl, alkoxy, halogen, haloalkyl, methylenedioxy, ethylenedioxy, ethyleneoxy or vinylenoxy;\n(iii) by substitution on the methylene group of the benzyl group by alkyl containing up to three carbon atoms;\n(iv) by substitution to any extent on the 1-phenyl ring by alkyl, alkoxy, halogen, haloalkyl, methylenedioxy, ethylenedioxy, ethyleneoxy or vinylenoxy;\n(v) by replacement of the benzyl group by a 3,3-diphenylpropyl, a 3,3-diphenyl-3-cyanopropyl or a 4-alkyl-4-oxo-3,3-diphenylbutyl group.”.\n(3) In Part 2 (which specifies the drugs which are subject to control as Class B drugs)—\n(a) in paragraph 1(aa)(ii) after “alkyl substituent” insert “or by inclusion of the carbon atom at the 3- position in a phenyl ring”;\n(b) in paragraph 1(ab)(ii) after “alkyl substituent” insert “or by inclusion of the carbon atom at the 3- position in a phenyl ring”;\n(c) after paragraph 1(e) insert—\n“(f) The compounds listed below save where they are contained in cannabis or cannabis resin—\n(i) Hexahydrocannabinol (HHC);\n(ii) Hexahydrocannabiphorol (HHCP);\n(iii) Hexahydrocannabihexol (HHCH);\n(iv) 9-Hydroxyhexahydrocannabinol (9-OH-HHC);\n(v) 10-Hydroxyhexahydrocannabinol(10-OH-HHC);\n(vi) 11-Hydroxyhexahydrocannabinol (11-OH-HHC);\n(vii) 10-Hydroxyhexahydrocannabiphorol (10-OH-HHCP);\n(viii) Hexahydrocannabinol-C8 (HHC-C8);\n(ix) Hexahydrocannabinol-C9 (HHC-C9);\n(x) 11-Hydroxy tetrahydrocannabinol (11-OH-THC);\n(xi) Tetrahydrocannabinolic acid A (THC acid A, 1-hydroxy-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6[H]-benzo(c)chromene-2-carboxylic acid);\n(xii) Tetrahydrocannabinolic acid B (THC acid B, 1-hydroxy-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6[H]-benzo(c)chromene-4-carboxylic acid).”;\n(d) in paragraph 2A for “or (d)” substitute “, (d) or (f)”.\n(4) In Part 3 (which specifies the drugs which are subject to control as Class C drugs)—\n(a) in paragraph 1(a), at the appropriate places in the list, insert—\n“Carisoprodol.”;\n“Detomidine.”;\n“Ethylbromazolam.”;\n“Etomidate.”;\n“Medetomidine.”;\n“Zuranolone.”;\n(b) in paragraph 1(e), at the appropriate places in the list, insert—\n“Lonapegsomatropin.”;\n“Somapacitan.”;\n“Somatrogon.”.\n(5) In Part 4 (which sets out the meaning of certain expressions used in Schedule 2), for the definition of “cannabinol derivatives” substitute—\n““cannabinol derivatives” means any substance (not being a substance mentioned in another entry in paragraph 1(a) or in paragraph 1(c) or (f) of Part 2 of this Schedule or contained in cannabis or cannabis resin) which is either or both of the following—\n(a) a tetrahydro or hexahydro derivative of cannabinol including those derivatives substituted by a hydroxy group at the 11- position;\n(b) a 3-alkyl homologue of cannabinol or of its tetrahydro or hexahydro derivatives including those derivatives substituted by a hydroxy group at the 11- position;”.",
  "extent": null,
  "status": null,
  "version": "current",
  "annotations": [
    {
      "type": "footnote",
      "label": "f1",
      "text": "Sub-paragraph (a) of paragraph 1 was designated as such by S.I. 1977/1243. Relevant amending instruments are S.I. 1984/850, 1986/2230 and 2024/190. There are other amendments to Part 1 of Schedule 2 which are not relevant to this Order."
    },
    {
      "type": "footnote",
      "label": "f2",
      "text": "Sub-paragraph (ea) was inserted by S.I. 2024/1361."
    },
    {
      "type": "footnote",
      "label": "f3",
      "text": "Relevant amending instruments are S.I. 2008/2130, 2010/1207, 2010/1833, 2013/239 and 2014/1106. There are other amendments to Part 2 of Schedule 2 but none are relevant."
    },
    {
      "type": "footnote",
      "label": "f4",
      "text": "Sub-paragraph (a) of paragraph 1 was designated as such by S.I. 1996/1300. There are other amendments to Part 3 of Schedule 2 but none are relevant."
    }
  ],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/ukdsi/2026/9780348288254/article/2",
    "retrieved_at": "2026-10-31T10:26:41.755970+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}